Q3 2025 13F Holders as of 9/30/2025
-
Type / Class
-
Equity / Common Stock, $0.001 par value per share
-
Shares outstanding
-
59.7M
-
Number of holders
-
132
-
Total 13F shares, excl. options
-
59.4M
-
Shares change
-
-50.8K
-
Total reported value, excl. options
-
$1.22B
-
Value change
-
-$295K
-
Number of buys
-
77
-
Number of sells
-
-41
-
Price
-
$20.47
Significant Holders of Enliven Therapeutics, Inc. - Common Stock, $0.001 par value per share (ELVN) as of Q3 2025
143 filings reported holding ELVN - Enliven Therapeutics, Inc. - Common Stock, $0.001 par value per share as of Q3 2025.
Enliven Therapeutics, Inc. - Common Stock, $0.001 par value per share (ELVN) has 132 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 59.4M shares
of 59.7M outstanding shares and own 99.4% of the company stock.
Largest 10 shareholders include ORBIMED ADVISORS LLC (7.96M shares), FMR LLC (7.13M shares), Commodore Capital LP (4.69M shares), Fairmount Funds Management LLC (3.71M shares), BlackRock, Inc. (3.52M shares), VR ADVISER, LLC (3.23M shares), Polar Capital Holdings Plc (3.1M shares), VANGUARD GROUP INC (2.55M shares), JANUS HENDERSON GROUP PLC (1.79M shares), and NOVO HOLDINGS A/S (1.43M shares).
This table shows the top 132 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.